Research Use Only: This product is supplied for laboratory research and in-vitro studies. Not for human or veterinary administration.
Semax 30mg
- ACTH(4-10) Analogue: Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, developed 1982 Russian Academy, ACTH(4-7) + Pro-Gly-Pro extension for metabolic stability, 800+ publications, no hormonal activity
- Multi-Modal Neuroprotection: BDNF upregulation (1.4× protein, 3× mRNA hippocampus), monoamine modulation (180% 5-HIAA), copper chelation (K_D 1.3×10⁻¹⁵ M), anti-amyloid activity, transcriptomic ischemia protection
- Clinical Status: Russian FDA approved, List of Vital & Essential Drugs 2011, Phase I-II trials 1990-1996, extensive clinical use for stroke/cognitive disorders/optic neuropathy, low toxicity profile
- Metabolic Synergy Research
- In-Vitro Receptor Profiling
- HPLC Verified (≥98% Purity)
Ships same-day if ordered before 2PM EST
Research Overview
Semax (ACTH(4–7)-PGP; also referenced as Pro-Gly-Pro-ACTH in registry records) is a synthetic heptapeptide derived from a defined segment of adrenocorticotropic hormone (ACTH). In the scientific literature, Semax has been used as a research tool in neurobiology and molecular signaling studies, including investigations of activity-dependent gene programs, neurotrophin-linked transcriptional responses, monoaminergic pathway markers, and systems-level network activity measured with experimental imaging and omics approaches.
Preclinical publications describe Semax-associated changes in transcriptional signatures across CNS-relevant tissues and report modulation of neurotrophin-related gene expression (including BDNF and NGF) in controlled animal and cell-based experimental designs.